Pipeline
Debiopharm’s projects cover all molecule type proteins, peptides, small molecules
Oncology
Program
Indication
Mode of Action
Discovery
Preclinical
Phase I
Phase II
Phase III
_ naratuximab emtansine (Debio 1562)
Diffuse large B-cell lymphoma – Anti-CD37 ADC
Anti-CD37 ADC
ODD
_ naratuximab emtansine (Debio 1562M)
Oncology – anti-CD37 ADC/Multilink
anti-CD37 ADC/Multilink
_ Debio 4326
Central Precocious Puberty – 12M GnRH agonist analogue
12M GnRH agonist analogue
_ Debio 0432
Oncology – USP-1 inhibitor
USP-1 inhibitor
_ Debio 4126
Acromegaly – Synthetic Somatostatin analogue
Synthetic Somatostatin analogue
_ Debio 4127
Gastroenteropancreatic neuroendocrine tumor – Synthetic Somatostatin analogue
Synthetic Somatostatin analogue
_ Debio 4228
Oncology – Undisclosed
Undisclosed
_ Debio 0228
Oncology – CAIX-targeted radiotherapy
CAIX-targeted radiotherapy
_ Debio 4028
Oncology – IAP antagonist
IAP antagonist
Merck
ODD: Orphan Drug Designation
Merck: Merck KGaA
Enabling Technologies
Program
Indication
Mode of Action
Prototype
Preclinical
Phase I
Phase II
Phase III
_ Multilink™
Multidrug linker platform – Multipayload linker for ADC
Multipayload linker for ADC
Genome/Ubix
_ AbYlink™
Diagnostic and therapeutic antibody conjugation technology – Antibody conjugation
Antibody conjugation
Genome: Genome & Company
Ubix: Ubix Therapeutics
Infectious disease
Program
Indication
Mode of Action
Discovery
Preclinical
Phase I
Phase II
Phase III
_ afabicin (Debio 1450)
Bone & joint infections – FabI inhibitor
FabI inhibitor
ODD/FT/QIDP
_ afabicin (Debio 1450)
ABSSSI – FabI inhibitor
FabI inhibitor
FT/QIDP
_ Debio 1453
N. gonorrhoeae – Fabl inhibitor
Fabl inhibitor
CARB-X
_ Debio 1454/S
A. baumannii – Fabl inhibitor
Fabl inhibitor
CARB-X
_ Debio 1454/M
GI disorders – microbiome remodeling
microbiome remodeling
Takeda
_ FibroTrap™ (Debio 1561)
Infectious diseases – Sample prep. Technology
Sample prep. Technology
ODD: Orphan Drug Designation
FT: Fast-Track
QIDP: Qualified Infectious Disease Product
CARB-X: CARB-X
Takeda: Takeda